Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Infection
; 51(5): 1577-1581, 2023 Oct.
Article
em En
| MEDLINE
| ID: mdl-37076752
ABSTRACT
PURPOSE:
People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status.RESULTS:
We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly.CONCLUSIONS:
Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Linfoma Folicular
/
Neoplasias Hematológicas
/
COVID-19
Limite:
Humans
Idioma:
En
Revista:
Infection
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Itália